Clinical trials: Community Acquired Pneumonia (CAP)
Community Acquired Pneumonia (CAP), Acute Exacerbation of Chronic Bronchitis (AECB)
Ketek in CAP / AECB in Ambulatory Adult Patients
To determine the clinical effectiveness of telithromycin in the treatment of either CAP or AECB in a large population of ambulatory adult patients in a community-based setting.
- Trial name
- NCT00546676
- Testing
- Telithromycin
- Volunteers
- 174 people
- Sponsor
- Sanofi
Community Acquired Pneumonia (CAP)
Clinical Characteristics and Outcome of Patients With Community Acquired Pneumonia
the goal of this observational study is to evaluate the clinical characteristic and outcomes of patients with community-acquired pneumonia admitted to Sohag University Hospital.
- Trial name
- NCT06716099
- Volunteers
- 100 people
- Sponsor
- Sohag University
Community Acquired Bacterial Pneumonia
Use of Ceftaroline in Hospitalized Patients With Community Acquired Pneumonia
Community-acquired bacterial pneumonia, which is often called CAP, is a bacterial infection in the lungs and is treated with antibiotics. Sometimes people need to be in the hospital to be treated for CAP.
- Trial name
- CAP (NCT01605864)
- Testing
- Efficacy of ceftaroline
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Albany Medical College
Respiratory Infection, Pneumonia
Efficacy and Safety of Trimodulin (BT588) in Subjects With CAP Including COVID-19 Pneumonia
The main objectives of the trial are to assess the efficacy and safety of trimodulin as adjunctive treatment to standard of care (SoC) compared to placebo plus SoC in adult hospitalized subjects with non-severe community-acquired…
- Conditions
- Respiratory Infection, Pneumonia, Community-acquired Pneumonia, Acute Respiratory Distress Syndrome
- Trial name
- TRICOVID (NCT05531149)
- Testing
- Trimodulin
- Where
- 64 sites in Argentina, Austria and 12 more
- Volunteers
- 107 people
- Sponsor
- Biotest
Community-acquired Pneumonia
pedCAPNETZ - Community Acquired Pneumonia (CAP) in Childhood and Adolescence
Establishment of a study network and patient cohort for pediatric CAP
- Trial name
- pedCAPNETZ (NCT04047108)
- Where
- Germany
- Volunteers
- 1,000 people
- Sponsor
- Hannover Medical School
Pulmonary Disease, Infection
Leukocyte Morphological Parameters as Prognostic Markers in CAP
An innovative multicenter project that aims to study the evolution and predictive value of new leukocyte morphological parameters (CPD) in patients with community-acquired pneumonia.
- Trial name
- NCT04930926
- Where
- Spain
- Volunteers
- 1,200 people
- Sponsor
- Hospital Galdakao-Usansolo
Community Acquired Pneumonia
A Retrospective Study on Hospitalized Patients With Community-acquired Pneumonia in China (CAP-China)
The purpose of this study is to evaluate the disease burden of hospitalized patients with CAP and healthcare-associated pneumonia (HCAP) in real life of China .
- Trial name
- RSCAP-China (NCT02489578)
- Testing
- other
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- Capital Medical University
Community-acquired Pneumonia
Phase II Clinical Study to Assess the Efficacy and Safety of Nemonoxacin Malate in Treating Adult Patients With Community-acquired Pneumonia (CAP)
The purpose of this study is to evaluate the safety, tolerability and population pharmacokinetics of oral nemonoxacin in community-acquired pneumonia (CAP) subjects.
- Trial name
- NCT01537250
- Testing
- Nemonoxacin 3 tablets
- Where
- 32 sites in China
- Volunteers
- 192 people
- Sponsor
- TaiGen Biotechnology Co., Ltd.
Community-acquired Pneumonia (CAP), Hospital-acquired Pneumonia (HAP)
Ceftobiprole in the Treatment of Pediatric Patients With Pneumonia
This was a study of the safety and efficacy of ceftobiprole medocaril compared with intravenous (IV) standard-of-care cephalosporin treatment with or without vancomycin in pediatric patients with either hospital-acquired…
- Trial name
- NCT03439124
- Testing
- ceftobiprole medocaril, IV standard-of-care cephalosporin
- Where
- 19 sites in Bulgaria, Georgia and 2 more
- Volunteers
- 138 people
- Sponsor
- Basilea Pharmaceutica
D-dimer
Association Between Plasma D Dimer in Adult CAP and Severity of Inflammatory Response and Survival
This observational study aims to investigate the association between elevated plasma D-dimer levels and the inflammatory response, as well as its impact on survival in adult patients with community-acquired pneumonia.
- Trial name
- NCT07199530
- Testing
- Blood Product
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Ain Shams University
Bacterial Pneumonia
Comparative Study of Ceftaroline vs. Ceftriaxone in Adults With Community-Acquired Pneumonia
The purpose of the study is to determine if the antibiotic ceftaroline is safe and effective in the treatment of community-acquired pneumonia in adults.
- Trial name
- CAP (NCT00509106)
- Testing
- Ceftaroline fosamil for Injection, Ceftriaxone
- Where
- 134 sites in United States, Argentina and 13 more
- Volunteers
- 622 people
- Sponsor
- Forest Laboratories
Community-Acquired Pneumonia (CAP)
Clinical Trial of Fei Re Qing Granules in the Treatment of Elderly Community-Acquired Pneumonia
This study aims to evaluate the clinical efficacy of traditional Chinese medicine formula granules (Fei Re Qing Granules) in the treatment of elderly community-acquired pneumonia, establish a treatment protocol, and obtain…
- Trial name
- NCT06747325
- Testing
- Fei Re Qing Granules, Routine standard treatments
- Volunteers
- 120 people
- Sponsor
- Henan University of Traditional Chinese Medicine
Community Acquired Pneumonia in Children
Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP
The goal of this open label, randomized, non-inferiority clinical trial is to compare the treatment success of a 5 day antibiotic course versus a standard antibiotic course (usually 7-14 days of antibiotics) in hospitalized…
- Trial name
- NCT06494072
- Testing
- Ampicillin for Injection, Ceftriaxone for Injection, Amoxicillin
- Where
- United States
- Volunteers
- 236 people
- Sponsor
- Medical College of Wisconsin
Community-Acquired Pneumonia (CAP)
How Does Medical Clown Intervention Affect the Length of Hospitalization in Children With Pneumonia
Background and Objectives: Community-acquired pneumonia (CAP) is a leading cause of hospitalization in children. The hospitalization duration depends on factors as child's well-being, vital signs, need for parenteral treatments…
- Trial name
- NCT06750029
- Testing
- Medical clown visits
- Where
- Israel
- Volunteers
- 51 people
- Sponsor
- Carmel Medical Center
Community Acquired Pneumonia (CAP)
Local Antibiotic Delivery for Community Acquired Pneumonia
A randomized, double-blinded clinical pilot study to assess whether addition of inhaled levofloxacin 240 mg twice daily for three days leads to improved or worsened physiological status in CAP patients with and without…
- Trial name
- LANDCAP-1 (NCT06859450)
- Testing
- Levofloxacin
- Volunteers
- 36 people
- Sponsor
- Copenhagen Respiratory Research
Pneumonia
Study to Evaluate the Efficacy and Safety of Oral Administration With Nemonoxacin and Levofloxacin in Patients With CAP
1. This study will test the safety and efficacy of TG-873870 (Nemonoxacin) compared with Levofloxacin in adult patients with Community-Aquired Pneumonia (CAP) 2.
- Trial name
- NCT01529476
- Testing
- Levofloxacin, Nemonoxacin
- Where
- 57 sites in China, Taiwan
- Volunteers
- 540 people
- Sponsor
- TaiGen Biotechnology Co., Ltd.
Community-acquired Pneumonia (CAP)
Efficacy of High Doses Penicillin V Versus High Doses Amoxicillin in the Treatment of Non-severe Pneumonia.
This study aims to evaluate wether high-dose penicillin V is as effective as high-dose amoxicillin for the treatment of non-sever community-acquired pneumonia (CAP).
- Trial name
- PENIPNEUMO (NCT03208361)
- Testing
- Penicillin V, Amoxicillin
- Where
- Spain
- Volunteers
- 43 people
- Sponsor
- Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
COVID-19, Viral Pneumonia
Clinical, Molecular and Functional Biomarkers for PROgnosis, Pathomechanisms and Treatment Strategies of COVID-19 (PROVID) - (PROVID-CAPNETZ)
The pandemic triggered by the new SARS-CoV-2 presents the German health system with previously unknown challenges. There are currently no effective therapies for the treatment of the SARS-CoV-2 lung disease Covid-19.
- Conditions
- COVID-19, Viral Pneumonia, Pneumonia Due to Streptococcus Pneumoniae, Bacterial Pneumonia
- Trial name
- PROVID-CAPNETZ (NCT04952337)
- Where
- 15 sites in Germany
- Volunteers
- 400 people
- Sponsor
- Hannover Medical School
Respiratory Tract Diseases, Influenza (Pandemic)
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of hospitalised…
- Conditions
- Respiratory Tract Diseases, Influenza (Pandemic), Influenza, Community Acquired Pneumonia
- Trial name
- REMAP-CAP (NCT02735707)
- Testing
- Ceftriaxone + Macrolide, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam + Macrolide
- Where
- 408 sites in United States, Australia and 27 more
- Volunteers
- 20,000 people
- Sponsor
- UMC Utrecht
Acute Respiratory Distress Syndrome, Severe Community-Acquired Pneum
Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS)
This Phase 2 study tests whether adding two immune therapies - nogapendekin alfa-inbakicept (NAI) and off-the-shelf iNKT cell infusions - to standard care can safely help critically ill adults with severe community-acquired…
- Conditions
- Acute Respiratory Distress Syndrome, Severe Community-Acquired Pneum, Sepsis, Lymphopenia / Immunoparalysis in Critically Ill Adults
- Trial name
- NCT07492888
- Testing
- Nogapendekin Alfa-Inbakicept (NAI), Allogeneic invariant Natural Killer T (iNKT) Cells (AgenT-797)
- Sponsor
- ImmunityBio, Inc.